Latest News in the Business and Financial World

Thursday, February 25, 2021
Log in
  • Home
  • Company News & Financials
  • OTC Markets
  • Tech & Science
  • Health & LifeStyle
  • About WS OTC
    • Analysts & Contributors
    • Contact Us
    • Advertising
    • Feedback
    • Privacy Policy GDPR
  • Mobile
  • Latest News
    • New Theories Explain the Disappearance of the Mayan Civilization
    • What Happens If Coral Reefs Die?
    • Monsanto Loses Lawsuit for its Herbicide Products
    • Mankind (MNKD) shares Plunge after FDA Approves Afrezza, inhaled Insulin for Diabetes patients
    • Psychologists Confirm that Violent Video Games Boost Aggressiveness
    • World of Warcraft: Warlords of Draenor Release Date on Nov 13
    • iPass Global Hotspot Map Unveils Worldwide Wi-fi Coverage

Pages

  • About Wall Street OTC
  • Advertising
  • Analysts & Contributors
  • Contact
  • Feedback
  • Mobile
  • Privacy Policy GDPR
  • Terms of Service

Recent Posts

  • SF Hospital Slaps New Parents with $19K Bill for Baby Treatment
  • Furious Trump Blasts Harley-Davidson for Moving Production Overseas
  • Warning! MRI Machines Could Poison You
  • Flight Attendants More Likely to Get Certain Cancers
  • More Red Meat Allergy Cases Related to Lone Star Tick Bites

Gulf Resources Inc. Shares Soar Almost 30% After Q1 Net Earnings Double

Jun 6, 2014 By Kevin Calderon Leave a Comment

Gulf Resources Inc. (GURE) shares continued to power higher on Monday, gaining 27%, after strong Q1 results reported Friday. 

Shares of the manufacturer of specialty products in China rose to $2.26 per share Monday after gaining 11% after hours on Friday. The stock is trading near the top end of the 52-week spread between $1.04 and $3.20. 

Net income was $4.3 million, or $0.11 per basic and diluted share, compared to $1.9 million, or $0.05 a year ago. 

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: China rose, Gulf Resources Inc., GURE, Net income

MannKind Posts Q1 Loss

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

MannKind (MNKD) shares were up 0.3% at $6.24 in pre-market trade Monday after it reported a Q1 loss. 

The net loss applicable to common stockholders for Q1 2014 was $52.1 million, or $0.14 per share based on 368.8 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $41.0 million, or $0.15 per share based on 280.1 million weighted average shares outstanding for Q1 2013. 

MNKD trades in a 52-week range of $3.80 to $8.70. 

The Street estimates were not available.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: common stockholders, MannKind, MNKD

Alnylam Pharmaceuticals Gains 8% as Hepatitis B Treatment Shows Promise on Chimpanzees

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Alnylam Pharmaceuticals, Inc (ALNY) shares are up almost 8% pre-market after the company reported positive results from a trial of its ALN-HBV for the treatment of hepatitis B virus in chimpanzees. 

“Alnylam’s new ALN-HBV program is a mature, pre-clinical asset acquired through the company’s acquisition of Sirna from Merck. We are very encouraged by the data we are presenting for the first time today, which we believe constitute the most robust proof-of-concept pre-clinical data to date with an RNAi therapeutic for the treatment of HBV,” said company vice president Laura Sepp-Lorenzino. 

The stock recently traded at $58.50 and has moved in a 52-week range of $25.57 – $112.57.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: ", ALN-HBV program, ALNY, Alnylam Pharmaceuticals, HBV, Inc., Merck, Sirna

3D Systems Higher in Pre-Bell – Inks Distribution Pact with ScanSource

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

3D Systems (DDD) is higher this morning after it announced a partnership with ScanSource (SCSC) to collaborate on the sale and support of 3D printing solutions. No financial terms were disclosed.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: 3D printing solutions, 3D Systems, DDD, ScanSource, SCSC

Peabody Energy Upgraded to Overweight at Morgan Stanley, PT Raised $10 to $30; Shares Spike 4% Early

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Peabody Energy Corporation (BTU) has been upgraded by Morgan Stanley to an overweight rating from an equalweight rating. 

The firm also boosted the price target on shares of the private sector coal company by 50% to $30 from $20. 

In pre-market activity, shares of BTU are up 3.75% to $19.36, and have a 52-week trading range of $14.34 – $21.84.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: BTU, equalweight rating, Morgan Stanley, Peabody Energy Corporation

Vectren Corporation Q1 Earnings Miss Views While Sales Easily Beat Estimates

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Vectren Corporation (VVC) reported Q1 earnings that missed analysts’ expectations even as sales were well ahead of estimates. 

VCC traded lower 0.4%, in the upper half of the 52-week range between $31.83 and $41.14. 

The owner of among others public utlities said its Q1 earnings rose modestly to $51.2 million or $0.62 per share from $49.8 million or $0.61 per share amid higher operating expenses. Analysts polled by Capital IQ had expected EPS of $0.74 per share. Sales were $796.8 million compared to $700.6 million a year ago, exceeding the $750 million average estimate. 

“We fully expect that the infrastructure services work that was delayed in the first quarter as a result of the weather, along with other work, will be largely completed over the remainder of the year as there continues to be very high demand for those services,” CEO Carl Chapman said in a statement. 

Vectren reaffirmed its FY14 guidance of consolidated earnings between $2.15 and $2.35 per share compared to the $2.27 average estimate from analysts polled by Capital IQ.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: VCC, Vectren Corporation

Core Laboratories Drops 12% Pre-Bell After Cutting 2014 EPS, Revenue Guidance

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Core Laboratories (CLB) shares are down more than 12% after the company cut its 2014 revenue and earnings guidance after an unexpectedly weak performance in April. 

Core, which provides reservoir management services to the oil and gas industry, expects Q2 2014 EPS to be in the $1.32 – 1.35 range with revenue ranging from $265 million to $270 million. 

Analysts were looking for Q2 EPS of $1.51 on revenue of $285 million. 

Full year EPS is expected to range from $5.80 to $6.00 with revenue of approximately $1.1 billion. That’s below the consensus forecast for EPS of $6.20 and revenue of $1.2 billion. 

The shares recently traded at $166.00 in a 52-week range of $133.02 – $221.00

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: CLB, Core Laboratories

Analyst Actions: Intersil Up 3% on Citigroup Upgrade to Neutral from Sell

Jun 6, 2014 By Anne-Marie Jackson 1 Comment

Intersil (ISIL) shares were up 3% at $13.15 late in Friday’s session after shares were upgraded to Neutral from Sell at Citigroup, which has a $14 price target. 

Intersil manufactures and markets analog, mixed-signal, and power management integrated circuits. 

ISIL trades in a 52-week range of $7.28 to $13.58.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: Citigroup, Intersil, ISIL, Neutral, Sell

Chefs’ Warehouse Files to Announce Late Earnings – Stock Down 3%

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

The Chefs’ Warehouse, Inc. (CHEF), a distributor of specialty food products, said it filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with the company’s Quarterly Report on Form 10-Q for the quarter ended March 28, 2014. The Company’s quarterly report was due on May 7, 2014. 

Based on information the Company reviewed as part of the procedures for preparing the report on Form 10-Q for the quarter ended March 28, 2014, the Company has determined that the accrual for accounts payable at its Michael’s Finer Meats subsidiary may have been understated at quarter end by approximately $786,000. The Company is in the process of finalizing a detailed review of the accounts payable accrual and anticipates that it will file the report on Form 10-Q no later than five calendar days from the date that it was due. The effect of an understatement of the accrual for accounts payable by that amount would result in a reduction to net income by approximately $460,000 and net income per share by approximately $0.02 per share from the results that the Company preliminarily reported on May 1, 2014. 

The impact of the accrual does not affect the Company’s previously issued financial guidance for fiscal year 2014. 

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: CHEF, Inc., Notification of Late Filing, The Chefs' Warehouse

Molycorp Slips 19% on Downgrade to Underweight from Neutral at JPMorgan Chase

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Molycorp (MCP) shares plunged 19% in Friday’s session, hitting a 52-week low of $3.01, as shares were downgraded to Underweight from Neutral at JPMorgan Chase & Co. 

It’s the second day of declines for Molycorp. Shares traded about 18% lower Thursday after reporting a bigger than expected loss for Q1. 

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: JPMorgan Chase & Co, MCP, Molycorp

Erickson Swings to Adjusted Q1 Loss – Stock Drops 5%

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Helicopter manufacturer Erickson Inc. (EAC) drops nearly 5% Friday after swinging to an adjusted loss from a narrow profit a year earlier. 

EAC reported a Q1 net loss of $7.6 million, or $0.55 per diluted share, as compared to a net loss of $1.2 million, or $0.13 per diluted share in the prior year’s Q1. The company’s adjusted net loss was $7.1 million, or $0.52 per diluted share compared to a profit of $0.01 in the same period a year earlier. Analyst estimates were not available. 

The stock neared a test of its $14.10 52-week low.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: EAC, Erickson Inc., Helicopter manufacturer

Shire Edges Up Pre-Bell Following Lumena Pharmaceuticals Buy

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

American Depositary Shares of Shire (SHPG) edged up 0.3% in recent pre-market trading on Monday, following the biopharmaceutical company’s acquisition of Lumena Pharmaceuticals, a company with late stage rare disease pipeline assets. 

SHPG will acquire Lumena for an upfront payment of $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials. It does not expect the acquisition of Lumena to result in a change to its previously stated earnings guidance for 2014. 

SHPG closed at $168.15 Friday, in a 52-week range of $91.81 – $180.91. 

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: American Depositary Shares, biopharmaceutical company, Lumena, Lumena Pharmaceuticals, Shire, SHPG

Gogo Inc. Reports Narrower Loss, Beats Street on Revenues; Shares Up Nearly 5% Pre-Bell

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Gogo Inc. (GOGO) has reported a Q1 loss per share of $0.20, narrower than the loss of $4.77 per share in Q1 2013 and the $0.25 per share predicted by analysts for Q1 2014. Total revenue of $95.7 million was up from $70.8 million in Q1 2013 and beat analyst estimates of $94.03 million. 

The company has reaffirmed full-year guidance of total revenue of $400 million to $422 million. The Street is at $413 million. 

“We expect continued strong growth in revenue fueled by strong secular trends and passenger adoption of new services,” said President and CEO Michael Small. “We continue to add capacity by upgrading aircraft to ATG-4 technology and had 534 aircraft equipped with ATG-4 systems at the end of March. We expect to see significant capacity increases with the introduction of our GTO and 2Ku airborne antennas, both of which are capable of delivering industry leading speeds of 70 mbps to the aircraft initially, and up to 100 mbps when spot beam Ku satellites are launched.” 

Shares of GOGO are up $0.57, or 4.78%, at $12.50 in pre-market trading with a 52-week range of $9.71 – $35.77. 

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: ATG-4 technology, GOGO, Gogo Inc.

Orange Down 1% Despite Upgrade to Neutral From Sell at UBS

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Orange (ORAN) shares were down about 1% in Friday’s session even after shares were upgraded to neutral from sell at UBS. 

ORAN trades in a 52-week range of $9.10 to $16.86, trading close to the top end of that range. Shares hit a session low of $16.43 before climbing for most of the session.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: ORAN, Orange, UBS

Amgen, AstraZeneca Achieve Positive Results in Phase 3 Study of Psoriasis Treatment

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

Amgen (AMGN) and AstraZeneca (AZN) report that their phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Primary endpoints were patients achieving at least a 75% improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75), and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment. 

Shares of both companies are flat in after-hours trade. 

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: Amgen, AMGN, AstraZeneca, AZN, brodalumab, phase 3 AMAGINE-1TM study, Physician Global Assessment

AIG Narrows CEO Candidates to Top 2 – Shares Down 2.5% in First Pre-Market Matches

Jun 6, 2014 By Anne-Marie Jackson Leave a Comment

AIG (AIG) has narrowed its search for its next CEO to succeed Robert Benmosche to two of its executives, Peter Hancock and Jay Wintrob, according to Dow Jones Newswires. 

Hancock runs the global property-casualty business while Wintrob runs the life-insurance and retirement business. 

AIG trades in a 52-week range of $41.53 to $53.33.

Filed Under: Company News & Financials, Diversified Financial, Micro Cap, OTC Exchange, OTC Markets, OTC Research, Small Cap, Uncategorized Tagged With: AIG, Dow Jones Newswires, Jay Wintrob, Peter Hancock

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 72 other subscribers

Mom holding newborn's hands

SF Hospital Slaps New Parents with $19K Bill for Baby Treatment

Jun 29, 2018 By Anne-Marie Jackson Leave a Comment

Harley-Davidson biker

Furious Trump Blasts Harley-Davidson for Moving Production Overseas

Jun 28, 2018 By Anne-Marie Jackson Leave a Comment

MRI machine

Warning! MRI Machines Could Poison You

Jun 27, 2018 By Anne-Marie Jackson Leave a Comment

Flight Attendants More Likely to Get Certain Cancers

Jun 27, 2018 By Anne-Marie Jackson Leave a Comment

Lone star tick sitting on a succulent leaf

More Red Meat Allergy Cases Related to Lone Star Tick Bites

Jun 26, 2018 By Anne-Marie Jackson Leave a Comment

Time magazine cover

Time Admits Sobbing Cover Girl Was Not Separated from Parents

Jun 26, 2018 By Anne-Marie Jackson Leave a Comment

Sunshine and green leaves

Vitamin D Deficiency Could Boost Risk of Lung Disease

Jun 25, 2018 By Anne-Marie Jackson Leave a Comment

Green-light laser pointer

Greek Boy’s Retina Severely Damaged by Laser Pointer

Jun 22, 2018 By Anne-Marie Jackson Leave a Comment

Red Tesla car

Tesla Suing ‘Whistleblower’ over Data Theft

Jun 21, 2018 By Anne-Marie Jackson Leave a Comment

Boiled eggs and mayonnaise

Eating too Clean Can Lead to Orthorexia

Jun 20, 2018 By Anne-Marie Jackson Leave a Comment

NYC mayor Bill de Blasio

NYC Will Allow People to Smoke Pot in Public

Jun 20, 2018 By Anne-Marie Jackson Leave a Comment

A kitten and a puppy sleeping in a bed while hugging each other

Who Is Smarter Between Cats and Dogs? Researchers Have an Answer (Study)

Jun 19, 2018 By Anne-Marie Jackson Leave a Comment

Orthodox church in Greece

Being Religious Is Tied to Longer Lifespan, Study

Jun 19, 2018 By Anne-Marie Jackson Leave a Comment

Bacon and eggs for breakfast

How Does the Keto Diet Work?

Jun 18, 2018 By Anne-Marie Jackson Leave a Comment

Categories

  • Business
  • Company News & Financials
  • Diversified Financial
  • Entertainment
  • Featured
  • Health & LifeStyle
  • Micro Cap
  • Mid Cap
  • National News
  • Nature
  • OTC Exchange
  • OTC Markets
  • OTC Research
  • Science
  • Small Cap
  • Sports
  • Tech & Science
  • U.S.
  • Uncategorized
  • Wall Street
  • World
  • World Indexes

Copyright © 2021 wallstreetotc.com

About · Privacy Policy · Sitemap · Terms of Service · Contact

This website uses cookies to ensure you get the best experience on our website. Learn more.